Chonnam National University Hospital

JLK received FDA 510(k) approval for its AI-based stroke solution JLK-PWI, marking the fourth approval this year. JLK-PWI automatically analyzes brain MR perfusion images, crucial for timely stroke diagnosis. A study showed JLK-PWI's superior lesion detection over Rapid AI. JLK aims to establish itself as a full-cycle stroke solution provider in the U.S., leveraging the lucrative AI healthcare market.

A research team led by Ho Sang Jung has developed a non-invasive cancer diagnostic method using a specialized sensor material that amplifies optical signals of cancer metabolites in biofluids like saliva. This technology has shown diagnostic capability for colorectal and lung cancers, and has potential for other diseases with poorly understood diagnostics. The team also achieved high sensitivity and specificity in urine diagnostics for multiple cancers.

A multicenter, randomized, double-blind study evaluated the antihypertensive efficacy and safety of AML plus CC versus AML monotherapy in Korean patients with uncontrolled essential hypertension. Patients underwent a 4-week AML monotherapy run-in period, followed by randomization to combination therapy or AML monotherapy for 8 weeks. The primary outcome was DBP change at week 8, with additional assessments at weeks 4, 12, and 16. Safety was monitored through adverse events. The study aimed for KMFDS approval for the AML/CC fixed-dose combination.